Founded in 2019, NCITA is a national multi-site network of clinical imaging infrastructures, supported by a Cancer Research UK Accelerator Award of up to £10 million over 5 years.
Our integrated infrastructure provides support for multicentre imaging biomarker trials using single or multimodality imaging, quality assured protocols and repository support.
Our Exemplar projects and projects adopted by the NCITA infrastructure aim to deliver standardised, quality assured imaging biomarkers for improving patient care in areas of unmet clinical need.
NCITA's vision is to accelerate the standardisation and clinical translation of cancer imaging biomarkers to improve diagnosis and healthcare outcomes for patients
.
The NCITA consortium brings together nine leading UK cancer imaging institutions with complementary multimodality medical imaging technologies, expertise, training and data management services necessary to accelerate the standardisation and validation of cancer imaging biomarkers for clinical use. The NCITA infrastructure team work closely with NHS Hospital Trusts across the UK to develop new imaging technologies for improving patient care.
The NCITA infrastructure provides clinical researchers with access to world-class medical imaging technologies including whole-body magnetic resonance imaging (WB-MRI), hyperpolarized 13C MRI, multi-parametric MRI, oxygen-enhanced MRI and other MRI techniques (e.g. hyperpolarized xenon, CEST-MRI), positron emission tomography (PET), PET-MRI and PET-CT (PET-computed tomography) and novel CT (e.g. perfusion CT).
To find out more about NCITA’s infrastructure support for multicentre clinical imaging research, view our NCITA Brochure as well as our NCITA Comment Article published in the British Journal of Cancer, 2021.